AR110967A1 - Anticuerpos miméticos fgf21 y su uso - Google Patents

Anticuerpos miméticos fgf21 y su uso

Info

Publication number
AR110967A1
AR110967A1 ARP180100294A ARP180100294A AR110967A1 AR 110967 A1 AR110967 A1 AR 110967A1 AR P180100294 A ARP180100294 A AR P180100294A AR P180100294 A ARP180100294 A AR P180100294A AR 110967 A1 AR110967 A1 AR 110967A1
Authority
AR
Argentina
Prior art keywords
antibody
seq
amino acid
acid sequence
binding fragment
Prior art date
Application number
ARP180100294A
Other languages
English (en)
Inventor
David Langdon Yowe
Stephane Olland
Regis Cebe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR110967A1 publication Critical patent/AR110967A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une a b-klotho, en donde el anticuerpo o fragmento de unión a antígeno del mismo comprende: una CDR1 de cadena pesada (HCDR1) que comprende la secuencia de aminoácidos de SEQ ID Nº 6, 9, 10 ó 12; una CDR2 de cadena pesada (HCDR2) que comprende la secuencia de aminoácidos de SEQ ID Nº 7, 11 ó 13; una CDR3 de cadena pesada (HCDR3) que comprende la secuencia de aminoácidos de SEQ ID Nº 8 ó 14; una CDR1 de cadena ligera (LCDR1) que comprende la secuencia de aminoácidos de SEQ ID Nº 19, 31, 22 ó 25; una CDR2 de cadena ligera (LCDR2) que comprende la secuencia de aminoácidos de SEQ ID Nº 20 ó 23; y una CDR3 de cadena ligera (LCDR3) que comprende la secuencia de aminoácidos de SEQ ID Nº 21 ó 24. Reivindicación 24: Una composición farmacéutica que comprende un anticuerpo o fragmento de unión a antígeno del mismo de una de las reivindicaciones precedentes y un vehículo farmacéuticamente aceptable. Reivindicación 25: Un método para tratar un trastorno metabólico que comprende administrar a un sujeto afectado con un trastorno metabólico una cantidad eficaz de una composición farmacéutica que comprende un anticuerpo o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 - 23. Reivindicación 28: Un método para tratar un trastorno cardiovascular que comprende administrar a un sujeto que padece un trastorno cardiovascular una cantidad eficaz de una composición farmacéutica que comprende un anticuerpo o fragmento de acuerdo con cualquiera de las reivindicaciones anteriores. Reivindicación 43: Un método para preparar un anticuerpo o un fragmento de unión a antígeno del mismo que se une a b-klotho, que comprende la etapa de cultivar la célula huésped de la reivindicación 41 en condiciones adecuadas para la expresión del anticuerpo o un fragmento del mismo.
ARP180100294A 2017-02-08 2018-02-08 Anticuerpos miméticos fgf21 y su uso AR110967A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762456609P 2017-02-08 2017-02-08

Publications (1)

Publication Number Publication Date
AR110967A1 true AR110967A1 (es) 2019-05-22

Family

ID=61244657

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100294A AR110967A1 (es) 2017-02-08 2018-02-08 Anticuerpos miméticos fgf21 y su uso

Country Status (14)

Country Link
US (3) US10899844B2 (es)
EP (1) EP3580237A1 (es)
JP (1) JP6991246B2 (es)
KR (1) KR102572663B1 (es)
CN (1) CN110520443B (es)
AR (1) AR110967A1 (es)
AU (1) AU2018218557B9 (es)
BR (1) BR112019016344A2 (es)
CA (1) CA3052911A1 (es)
IL (3) IL292067B2 (es)
MX (1) MX2019009498A (es)
TW (1) TWI786087B (es)
UY (1) UY37598A (es)
WO (1) WO2018146594A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3164941A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
TW202334205A (zh) * 2021-12-30 2023-09-01 大陸商上海津曼特生物科技有限公司 抗βKlotho抗體及其應用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
MX9700764A (es) 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
WO2008123625A1 (ja) 2007-04-06 2008-10-16 National Institute Of Advanced Industrial Science And Technology 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
EP2506861A1 (en) 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
MX2012011986A (es) 2010-04-15 2013-03-05 Amgen Inc RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
CN103282055A (zh) 2010-11-05 2013-09-04 CovX科技爱尔兰有限公司 抗糖尿病化合物
AU2012254160A1 (en) 2011-05-10 2013-11-21 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of FGFR1 and beta-Klotho
ES2628385T3 (es) 2011-05-16 2017-08-02 F. Hoffmann-La Roche Ag Agonistas de FGFR1 y procedimientos de uso
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2012177481A2 (en) 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US20140206023A1 (en) 2013-01-24 2014-07-24 Ping Gao Methods, Kits & Antibodies for Detecting Intact Fibroblast Growth Factor 21
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI787590B (zh) * 2013-12-27 2022-12-21 日商中外製藥股份有限公司 等電點低之抗體的精製方法
CN106662577B (zh) * 2014-01-24 2020-07-21 恩格姆生物制药公司 结合蛋白及其使用方法
EP3122776B1 (en) 2014-03-25 2021-04-28 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2016054660A1 (en) 2014-10-03 2016-04-07 Surespot, Inc. Parking assignment system with laser rangefinder and parking meter
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2017021893A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
SI3334431T1 (sl) 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka

Also Published As

Publication number Publication date
AU2018218557A1 (en) 2019-08-22
JP6991246B2 (ja) 2022-02-03
BR112019016344A2 (pt) 2020-04-07
UY37598A (es) 2018-09-28
RU2019127917A3 (es) 2021-07-01
AU2018218557B2 (en) 2021-05-27
IL304781A (en) 2023-09-01
IL292067B2 (en) 2024-01-01
WO2018146594A1 (en) 2018-08-16
US11692046B2 (en) 2023-07-04
CA3052911A1 (en) 2018-08-16
IL292067A (en) 2022-06-01
TWI786087B (zh) 2022-12-11
KR20190115471A (ko) 2019-10-11
IL268551A (en) 2019-09-26
US20230416407A1 (en) 2023-12-28
RU2019127917A (ru) 2021-03-09
TW201835103A (zh) 2018-10-01
JP2020506728A (ja) 2020-03-05
US20190040153A1 (en) 2019-02-07
US20210171659A1 (en) 2021-06-10
IL292067B1 (en) 2023-09-01
IL268551B (en) 2022-05-01
AU2018218557B9 (en) 2021-06-24
EP3580237A1 (en) 2019-12-18
KR102572663B1 (ko) 2023-09-01
CN110520443B (zh) 2023-07-25
MX2019009498A (es) 2019-10-02
US10899844B2 (en) 2021-01-26
CN110520443A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
IL277242B2 (en) Antibodies that bind cd39 and uses thereof
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
NZ608660A (en) Anti-cd48 antibodies and uses thereof
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
JP2017505125A5 (es)
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
AR110719A1 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
AR103713A1 (es) Anticuerpos contra tau y sus usos
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso